These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11565329)

  • 41. The clinical profile of the angiotensin II receptor blocker eprosartan.
    Hedner T
    J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
    Ruilope LM; Rosei EA; Bakris GL; Mancia G; Poulter NR; Taddei S; Unger T; Volpe M; Waeber B; Zannad F
    Blood Press; 2005; 14(4):196-209. PubMed ID: 16126553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.
    Bozkurt O; de Boer A; Grobbee DE; Kroon AA; Schiffers P; de Leeuw P; Klungel OH
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):101-8. PubMed ID: 19502258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin II receptor blockers: current perspective.
    Agrawal V; Manohar G; Kasliwal RR
    J Assoc Physicians India; 2003 Jul; 51():706-13. PubMed ID: 14621043
    [No Abstract]   [Full Text] [Related]  

  • 45. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H; Jones PG; Marso SP; O'Keefe JH
    J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
    Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [ACE inhibitors versus AR II antagonists. Their role in arterial hypertension].
    Carmona JP
    Rev Port Cardiol; 2000 Dec; 19 Suppl 2():II43-9. PubMed ID: 11301910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Angiotensin converting enzyme inhibitors for hypertension].
    Kobusiak-Prokopowicz M
    Pol Merkur Lekarski; 1997 Jan; 2(7):66-70. PubMed ID: 9296907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Angiotensin-converting enzyme inhibitors. Familiar drugs--new indications].
    Gregor P
    Cas Lek Cesk; 1998 Mar; 137(5):150-3. PubMed ID: 9588098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renoprotection with angiotensin type-1 receptor blockers in hypertension.
    Narain VS; Kochar A
    Indian Heart J; 2000; 52(1):89-92. PubMed ID: 10820943
    [No Abstract]   [Full Text] [Related]  

  • 52. Prevention of stroke and cancer: could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors?
    Achard JM; Pruna A; Fernandez LA; Hottelart C; Mazouz H; Rosa A; Andrejak M; Fournier A
    Am J Hypertens; 1999 Oct; 12(10 Pt 1):1050-3. PubMed ID: 10560795
    [No Abstract]   [Full Text] [Related]  

  • 53. Angiotensin-converting enzyme inhibitors and beta-blockers in cardiac asymptomatic patients with Duchenne muscular dystrophy.
    Fayssoil A
    Indian Heart J; 2010; 62(3):273. PubMed ID: 21275309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Application to the internist practice. The place of AT1 receptor antagonists].
    Dusleag H
    Pharm Unserer Zeit; 2001; 30(4):322-5. PubMed ID: 11499258
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapeutic advantages of AT1 blockers in hypertension.
    Kendall MJ
    Basic Res Cardiol; 1998; 93 Suppl 2():47-50. PubMed ID: 9833162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed.
    Opie LH
    BMJ; 2005 May; 330(7502):1270; author reply 1270-1. PubMed ID: 15920136
    [No Abstract]   [Full Text] [Related]  

  • 57. ACE inhibitors, AT1 receptor blockers, and the kidney.
    Hollenberg NK
    Nephrol Dial Transplant; 1997 Mar; 12(3):381-3. PubMed ID: 9075109
    [No Abstract]   [Full Text] [Related]  

  • 58. Angiotensin converting enzyme inhibitors: present status and future perspectives.
    Sharma S; Trehan V; Gupta U
    Indian Heart J; 1995; 47(5):509-16. PubMed ID: 8714512
    [No Abstract]   [Full Text] [Related]  

  • 59. [Is differentiation of ACE inhibitors based on their effects on the brain possible?].
    Unger T
    Fortschr Med; 1994 Dec; 112(34):504-6. PubMed ID: 7843678
    [No Abstract]   [Full Text] [Related]  

  • 60. Are all angiotensin-converting enzyme inhibitors interchangeable?
    Furberg CD; Pitt B
    J Am Coll Cardiol; 2001 Apr; 37(5):1456-60. PubMed ID: 11300461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.